Description
Specifications
| Form | Capsules, 60 per bottle |
| Made in | USA |
| Testing | Third-party identity and purity, every lot |
| BPC-157 | C₆₂H₉₈N₁₆O₂₂ · MW 1419.5 · CAS 137525-51-0 |
| KPV | C₁₆H₃₀N₄O₄ · MW 342.4 · CAS 67727-97-3 |
| Larazotide | C₃₂H₅₅N₉O₁₀ · MW 725.8 · CAS 258818-34-7 |
How Is This Blend Studied?
This tri-peptide blend is researched for combined effects on gut barrier integrity. BPC-157 is studied for cytoprotective effects on gut epithelium, KPV (the C-terminal fragment of alpha-MSH) for NF-κB signaling activity, and Larazotide as a zonulin-pathway tight-junction regulator that has also been investigated as an orally delivered peptide. Together, the blend is used in preclinical models of gut barrier function and intestinal permeability.
Storage
Keep the bottle sealed with the desiccant inside, in a cool, dry place away from light. Refrigeration at 2–8 °C extends stability.
FAQ
How is this different from BPC-157 or KPV alone?
Our single BPC-157 and KPV come as lyophilized powder in vials. This blend combines both with Larazotide in capsule form.
Is a Certificate of Analysis available?
Yes. Tap “View Certificate of Analysis” on this page for the current lot’s third-party COA.
Do you provide use or dosing guidance?
No. This product is sold strictly for laboratory research, and orders indicating human or animal use are cancelled.
For laboratory research use only. Not for human consumption.
